Mounjaro weight loss program

A quick overview of key details.

Mounjaro is a highly effective, UK licensed weight loss treatment. It has been shown in clinical trials to help achieve up to 22.5% body weight loss. It is the latest GLP-1 weight loss medication, and is used for people with a body mass index (BMI) over 30. It can also be prescribed for patients with a BMI of 27+ and a weight-related medical condition, such as high blood pressure or high cholesterol. The active ingredient tirzepatide is a registered trademark of Eli Lilly. It is known as Zepbound in the US, but launched in the UK under the brand name Mounjaro. It is used once weekly, as a subcutaneous (under the skin) injection.

Mounjaro weight loss pens mimic the action of GLP-1, a natural hormone produced in the gut. This innovative treatment promotes significant weight loss for patients by acting similarly to GLP-1. Its two main effects are: It helps regulate appetite, making it easier to eat less It makes you feel fuller for longer Both actions lead to eating fewer calories, which results in weight loss.

Mounjaro should only be used to support weight loss if lifestyle changes like regular exercise and diet haven't been successful. Other GLP-1 medications are also available in the UK, including Saxenda, Wegovy and Ozempic. Mounjaro can be used for patients who have a BMI of over 30, or in patients with a BMI over 27, and other risk factors such as: Diabetes type 2 High cholesterol Obstructive sleep apnoea High blood pressure

When using Mounjaro KwikPens to suppress appetite, you can expect to lose around 16-22.5% of your initial body weight after completing treatment. This is the most effective of all the released GLP-1 medications so far. These figures have been achieved by patients who have maintained on the highest strength of Mounjaro, which is the 15mg strength.

The dosage table below outlines the recommended titration for Mounjaro when used for weight loss.

The most common side effects with Mounjaro affect the digestive system. These can include things like nausea, vomiting, diarrhoea and constipation. Most patients should see these effects subside after a few days. Other common side effects include: Feeling weak or tired Dizziness Injection site reactions such as bruising, pain or a rash

Mounjaro (tirzepatide) is a once-weekly injection that can help regulate blood sugar and reduce appetite. It mimics two natural hormones—GLP-1 and GIP.

Mounjaro is licensed for type 2 diabetes in some regions and may also be used for weight management depending on local approvals and clinical assessment.

Mounjaro may be prescribed for adults with a BMI of 30+ (or 27+ with a weight-related condition), subject to clinical suitability.

Mounjaro activates two hormone pathways (GLP-1 and GIP), while Ozempic and Wegovy primarily target GLP-1. This difference may affect how people respond.

There is no single "strongest" option for everyone. Different medicines work differently for different people.

Mounjaro is typically injected once a week, on the same day each week, at any time of day, with or without food.

Mounjaro is injected under the skin in the stomach, thigh, or upper arm. Your clinician or pharmacist can demonstrate the correct technique.

General guidance is to take a missed dose as soon as possible within 4 days. If more than 4 days have passed, skip the missed dose and take your next dose as scheduled.

If you stop taking Mounjaro, your appetite and weight may gradually return to pre-treatment levels. Some people continue on long-term treatment based on ongoing clinical review.

Common side effects include nausea, diarrhoea, constipation, and stomach pain. These often improve as your body adjusts to treatment.

Some people find smaller meals, avoiding very fatty foods, and staying well hydrated can help. If nausea is severe or persistent, speak to your clinician.

Serious risks can include pancreatitis and gallbladder issues, and there is a rare risk of thyroid tumours. Mounjaro may not be suitable if you have a personal or family history of medullary thyroid cancer.

Mounjaro does not typically cause low blood sugar on its own, but the risk can increase if taken with insulin or certain diabetes medicines.

Keep Mounjaro in the fridge (2-8°C) until use. It can be stored at room temperature (below 30°C) for up to 30 days.

Yes. Keep it stored properly using an insulated travel bag with cool packs, and carry it in your hand luggage.

Mounjaro may be available on the NHS in limited circumstances, typically through specialist weight management services.

Private pricing varies by provider and dose. Our prices start from £169 per month.

Yes. Mounjaro is a prescription-only medicine and is not available over the counter.

Mounjaro is available through regulated private clinics, online pharmacies, and some NHS weight management programmes.